NTLA
Intellia Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.74
+0.47%0
Insider buys (3m)
5
Insider sells (3m)
-$506.6K
Net value (3m)
-5.6%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 24, 2026 | LEONARD JOHN M · director, officer: President and CEO | Sale | 19,890 | $13 |
| Aug 24, 2026 | LEONARD JOHN M · director, officer: President and CEO | Sale | 2,785 | $13 |
| Jul 24, 2026 | Dulac Edward J III · officer: EVP, Chief Financial Officer | Sale | 8,111 | $11 |
| Jul 6, 2026 | Dulac Edward J III · officer: EVP, Chief Financial Officer | Sale | 4,677 | $18 |
| Jul 6, 2026 | Dube Michael P · officer: VP, Chief Accounting Officer | Sale | 2,641 | $17 |
| Jun 10, 2026 | GOODMAN JESSE · director | A-Award | 9,200 | $0.00 |
| Jun 10, 2026 | Cohen Fred E · director | A-Award | 9,200 | $0.00 |
| Jun 10, 2026 | CHASE WILLIAM J · director | A-Award | 9,200 | $0.00 |
| Jun 10, 2026 | Keresty Georgia · director | A-Award | 13,300 | $13 |
| Jun 10, 2026 | CHASE WILLIAM J · director | A-Award | 13,300 | $13 |
| Jun 10, 2026 | Bhanji Muna · director | A-Award | 13,300 | $13 |
| Jun 10, 2026 | Bhanji Muna · director | A-Award | 9,200 | $0.00 |
| Jun 10, 2026 | Verwiel Frank · director | A-Award | 9,200 | $0.00 |
| Jun 10, 2026 | Goff Brian · director | A-Award | 13,300 | $13 |
| Jun 10, 2026 | Keresty Georgia · director | A-Award | 9,200 | $0.00 |
| Jun 10, 2026 | Verwiel Frank · director | A-Award | 13,300 | $13 |
| Jun 10, 2026 | Cohen Fred E · director | A-Award | 13,300 | $13 |
| Jun 10, 2026 | GOODMAN JESSE · director | A-Award | 13,300 | $13 |
| Jun 10, 2026 | Goff Brian · director | A-Award | 9,200 | $0.00 |
| Jan 7, 2026 | Dulac Edward J III · officer: EVP, Chief Financial Officer | Sale | 6,379 | $9.21 |
| Jan 7, 2026 | BASTA JAMES · officer: EVP, General Counsel | Sale | 10,397 | $9.21 |
| Jan 7, 2026 | Clark Eliana · officer: EVP, Chief Technical Officer | Sale | 9,515 | $9.21 |
| Jan 7, 2026 | LEONARD JOHN M · director, officer: President and CEO | Sale | 34,146 | $9.21 |
| Jan 7, 2026 | Lebwohl David · officer: EVP, Chief Medical Officer | Sale | 11,903 | $9.21 |
| Jan 7, 2026 | Cohen Fred E · director | Purchase | 150,000 | $9.35 |
| Jan 7, 2026 | Schultes Birgit C · officer: EVP, Chief Scientific Officer | Sale | 8,508 | $9.21 |
| Jan 7, 2026 | Dube Michael P · officer: VP, Chief Accounting Officer | Sale | 2,989 | $9.21 |
| Dec 12, 2025 | LEONARD JOHN M · director, officer: President and CEO | Sale | 32,832 | $9.47 |
| Dec 12, 2025 | LEONARD JOHN M · director, officer: President and CEO | M-Exempt | 49,959 | $6.83 |
| Dec 12, 2025 | LEONARD JOHN M · director, officer: President and CEO | Sale | 5,355 | $9.59 |
Institutional positioning
13F filings over the trailing two quarters
New 116Increased 268Reduced 154Sold out 29
| Filer | Action | Shares | Filed |
|---|---|---|---|
| ARK Investment Management LLC | Increased | 16,875,684 | Aug 14, 2026 |
| BlackRock, Inc. | Increased | 15,409,023 | Aug 7, 2026 |
| ARK INVESTMENT MANAGEMENT LLC | Increased | 14,509,247 | May 12, 2026 |
| BLACKROCK, INC. | Increased | 12,155,806 | May 13, 2026 |
| STATE STREET CORP | Increased | 9,234,987 | Aug 7, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | Increased | 7,332,401 | Aug 13, 2026 |
| STATE STREET CORP | Increased | 6,922,676 | May 15, 2026 |
| D. E. Shaw & Co., Inc. | Increased | 6,443,323 | Aug 14, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | New Position | 6,223,325 | May 8, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 6,028,586 | Aug 13, 2026 |
| D. E. SHAW & CO., INC. | Increased | 5,728,177 | May 15, 2026 |
| TWO SIGMA INVESTMENTS, LP | Increased | 5,235,348 | Aug 14, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 5,084,105 | May 15, 2026 |
| FMR LLC | Increased | 4,773,034 | Aug 13, 2026 |
| TWO SIGMA INVESTMENTS, LP | Increased | 4,705,901 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 24, 2026